✦ LIBER ✦

Model for end-stage liver disease score and posttransplant biliary complications

✍ Scribed by Vinay Sundaram; Jawad Ahmad

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 39 KB
Volume: 18
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.22454

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The model for end-stage liver disease sc

The model for end-stage liver disease score and posttransplant biliary complications

✍ Domingo Balderramo; Andres Cardenas 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Posttransplant biliary complications in

Posttransplant biliary complications in the pre- and post-model for end-stage liver disease era

✍ Vinay Sundaram; Deborah T. Jones; Nilesh H. Shah; Michael E. de Vera; Paulo Font 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

Biliary complications remain a cause of morbidity after liver transplantation. The aim of this study was to determine whether changes in clinical practice in the era of the Model for End-Stage Liver Disease (MELD) has affected biliary complications after liver transplantation. We retrospectively rev

Age, model for end-stage liver disease s

Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity

✍ Andrea DiMartini; Paulo Fontes; Mary Amanda Dew; Francis E. Lotrich; Michael de 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

Calcineurin-inhibiting immunosuppressive medications are the mainstay of posttransplant immunosuppression. Although these highly beneficial drugs are critical for posttransplant survival, significant numbers of transplant recipients experience side effects, some requiring a switch to a different imm

Clinically relevant differences in the M

Clinically relevant differences in the Model for End-Stage Liver Disease and Model for End-Stage Liver Disease–sodium scores

✍ Rhiana Garritsen; Andrei Tintu; Herold Metselaar; Geert Kazemier 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views

With interest, we read the article by Xiol et al. 1 regarding differences in serum measurements between different laboratories and their influence on the Model for End-Stage Liver Disease (MELD) and the Model for End-Stage Liver Disease incorporating serum sodium (MELD-Na). They reported significant

Reply: Clinically relevant differences i

Reply: Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease–sodium scores

✍ Xavier Xiol; Jose Castellote; Xavier Fuentes-Arderiu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 37 KB 👁 1 views

We thank Garritsen et al. 1 for their interest in our article about differences in Model for End-Stage Liver Disease (MELD) and Model for End-Stage Liver Disease-Sodium (MELD-Na) scores determined at 3 different laboratories. 2 We agree that one of the important messages of our article is the import

Model for end-stage liver disease except

Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score–based liver allocation system

✍ Claire Francoz; Jacques Belghiti; Denis Castaing; Olivier Chazouillères; Jean-Ch 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB 👁 1 views

Model for End-Stage Liver Disease (MELD) score-based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis. Except for extreme values, high pretransplant MELD scores do not signific